In summary, the simultaneous presence of NRG1 and high EGFR homodimers, or NRG1 with high levels of AREG or TGFαmay represent biomarkers to enrich for HNSCC patients to be treated with KTN3379, particularly in combination with cetuximab. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.